Navigation Links
Neuro Kinetics Releases Updated Version of Neuro-Otologic Control and Analysis Software
Date:5/18/2011

PITTSBURGH, May 18, 2011 /PRNewswire/ -- Neuro Kinetics, Inc. (NKI) (www.neuro-kinetics.com), manufacturers of noninvasive medical diagnostic equipment used worldwide for neuro-physiologic, neuro-otologic, vestibular and neurological testing, said today that it has released version 6.10 of its VEST™ control and analysis software.

Clinical specialists use NKI's I-Portal® devices and VEST software to conduct vestibular, oculomotor and optokinetic tests to detect and measure balance- and dizziness-related pathologies, as well as for research and validation of these tests to detect concussions or mild Traumatic Brain Injury (mTBI). 

"We take pride in being the innovative leader in our markets," said Vince Kytka, director, operations and marketing.  "With our updated software, we are enabling our clinical users around the world to do more for their patients."

The most significant upgrade is the enhancement of the Dynamic Unilateral Centrifugation with SVV test. It was modified so that the user can collect multiple (two to four) SVV data points during each eccentric position.  This allows for separate calculations of mean and standard deviation for each right, center and left patient positions. The results have also been added to the analysis and report feature in VEST.

Version 6.10 also includes improved user interfaces, including:

  • The optokinetic test analysis table is now sorted by OKN velocity for easier viewing.
  • The analysis simulation (animated playback of eye movement) page has been reorganized and relabeled for easier use during data review.

In addition, 10 bugs identified by Neuro Kinetics and its users over the past year have been fixed.  

Some of the fixes include:

  • The VNG eye video file saving error.
  • The upbeat and downbeat nystagmus labeling in the Gaze Horizontal, Gaze Vertical and Spontaneous Nystagmus Tests.
  • The SHA Test analysis was modified to delete full cycles instead of partial cycles.  

NKI has established a beta testing program with Bloomsburg and Gallaudet Universities and, as a result, 6.10 has gone through the most rigorous and extensive testing of any software version the company has introduced.  

NKI's first I-Portal® NOTC system with VEST 6.10 shipped last week and all warranty and software- subscription customers received instructions for the upgrade and are downloading it now.

For more information about VEST or any other NKI product or service, please contact Neuro Kinetics at +1.412.963.6649 or via e-mail to sales@neuro-kinetics.com.

ABOUT NEURO KINETICS, INC.

Neuro Kinetics, Inc. (NKI) is the world leader in eye-tracking technology and non-invasive neuro-otologic diagnostic testing.  Central to its product mix and technological advances is the premise that the eye is the portal to the brain.  Research has shown the detection of abnormal eye reflexes can indicate the presence of more than 200 diseases and medical conditions.

For more than 25 years, NKI has supplied multi-modal neuro-otologic diagnostic tools to audiologists, ENT's, neuro-otologists, neuro-ophthalmologists and neurologists around the globe.  The company's patented products include the I-Portal® NOTC (Neuro-Otologic Test Center), I-Portal® VNG (Video Nystagmography) and I-Portal® VOG (Video Oculography), along with related accessories, software, training and support services.

MEDIA CONTACT:

John Buckman
Buckman Communications, for Neuro Kinetics, Inc.
+ 1 412-381-2900 or jbuckman@buckman.biz


'/>"/>
SOURCE Neuro Kinetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurologix Announces First Quarter 2011 Financial Results
2. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
3. NeurogesX to Present at 10th Annual JMP Securities Research Conference
4. Ridge Diagnostics, Inc. CEO to Speak at Neurotech Investing and Partnering Conference
5. NeurogesX Reports First Quarter 2011 Results
6. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
7. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
8. Ortho-McNeil Neurologics Voluntarily Recalls Two Lots of TOPAMAX®
9. Reportlinker Adds Neurology Devices Market Outlook in United States to 2017 - Neurostimulation Devices, Interventional Neurology and Others
10. Reportlinker Adds Neuropathy Therapy Area Pipeline Report
11. Reportlinker Adds Europe Neurology Devices Market Outlook to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
(Date:5/27/2016)... The healthcare sector is large ... all falling under its umbrella.  A rather overlooked sector ... talked about, these healthcare companies are still trying to ... is by far the largest consumer of the healthcare ... ADMD), Nutranomics Inc. (OTC: NNRX), KollagenX Corp. (OTCQB: KGNX), ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... , ... Psoriasis: Targets and Therapy has published ... author Professor Luigi Naldi says “The review in Psoriasis: Targets and Therapy throws ... onset and the severity of psoriasis, and negatively influences the response to systemic ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... individuals’ genetic characteristics and the physical and behavioral worlds in which they ... In personalized medicine, diagnosing an individual’s disease depends on accurately assessing his ...
(Date:5/31/2016)... ... May 31, 2016 , ... More than 80 representatives of the ... and the Prevent Cancer Foundation held an event on National Hepatitis Testing Day outside ... of viral hepatitis, the leading cause of liver cancer. , Foundation leaders and the ...
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader in high ... Co., the leading provider of secure mobile remote access solution for Japan enterprises. ... CACHATTO remote access solution. Splashtop for CACHATTO will be available as an ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices to ... this approach has proven transformative, both for people who hear voices and for the ... used around the world, but it still lags in the United States. , Now, ...
Breaking Medicine News(10 mins):